Employees: 1,744
Size GuangYuYuan Chinese Herbal Medicine (600771.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $866M, the 2440th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.92 on 18 Nov 2026.
Performance Over six months the shares fell 25.7%, against -23.0% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue fell 5.5% over the last twelve months (peer median +3.6%); the operating margin is 4.5% (peer median -0.8%).
Valuation It trades at 38.3× forward earnings against a peer median of 24.7× (most expensive of 7).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.4 points below its cost of capital (10.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.31B | CN¥1.35B | CN¥1.20B | CN¥1.27B | CN¥1.12B |
| Revenue growth | — | +12% | -5% | +14% | — |
| Gross profit | CN¥891M | CN¥882M | CN¥861M | CN¥899M | CN¥734M |
| EBITDA | n/a | CN¥170M | CN¥144M | CN¥154M | -CN¥187M |
| Net income | CN¥63.2M | CN¥63.0M | CN¥74.5M | CN¥90.1M | -CN¥250M |
| Free cash flow | CN¥216M | CN¥191M | CN¥103M | CN¥214M | CN¥246M |
| Capital expenditure | CN¥7.60M | CN¥6.24M | CN¥8.78M | CN¥2.51M | CN¥8.67M |
| Total debt | CN¥41.4M | CN¥63.0M | CN¥77.8M | CN¥333M | CN¥564M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600771.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.6% | -10.5% | 7th lowest of 21 |
| 6-month return | -25.7% | -23.0% | 10th highest of 19 |
| Distance from 52-week high | -41.6% | -43.7% | 10th highest of 21 |
| Revenue growth (TTM) | -5.5% | +3.6% | 7th lowest of 19 |
| Operating margin | 4.5% | -0.8% | 7th highest of 19 |
| Forward P/E | 38.3× | 24.7× | most expensive of 7 |
| Growth the price implies (Req g, 7 yrs) | 31.7% | 10.1% | most demanding of 7 |
| Growth delivered (Del g) | +4.2% | +4.9% | 4th highest of 7 |
| Hurdle (Req g minus delivered) | +27.5 pp | -5.9 pp | 2nd most demanding of 7 |
| ROIC minus cost of capital | -4.4 pp | -2.3 pp | 6th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 38.3× | 31.7% | +4.2% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | n/a | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 34.9× | 2.4% | +12.4% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 28.1× | 17.7% | +22.7% |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 21.4× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 9.0× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 14.0× | -4.2% | +10.6% |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | n/a | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 29.0× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | n/a | 19.4% | -6.0% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |